A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma

Trial Profile

A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Ofranergene obadenovec (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOBE
  • Sponsors VBL Therapeutics
  • Most Recent Events

    • 19 Jun 2017 Results published in the Media Release.
    • 15 May 2017 According to a VBL Therapeutics media release, based on the current event rate in this trial, the company expect the interim analysis to occur in the third quarter of 2017.
    • 20 Apr 2017 According to a VBL Therapeutics media release, interim analysis from this trial is expected in mid-2017, and top-line results from the full dataset to be available in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top